PROMOMED topped the rating of pharmaceutical companies for the first seven months of 2026

The biopharmaceutical company PROMOMED became the leader of the rating of pharmaceutical manufacturers in January — July 2026, increasing its position by 24 points compared to the same period last year. Such data is provided by the analytical agency DSM Group. In monetary terms, the company's share reached 3.26%. Bayer AG dropped to the second line of the rating with a share of 3.23%, Nizhpharm and Abbott Laboratories also lost their positions.

PROMOMED has achieved a record volume growth of 214.5% in the first seven months of this year. According to the DSM Group, this is the best dynamics among the TOP 100 manufacturers.

This increase in sales in the market is also confirmed by PROMOMED's financial statements: in 2025, the Company's revenue increased by 75%, and in the first half of 2026, the growth was 76% compared to the same period last year.

Innovative drugs in the treatment of type 2 diabetes and obesity remain the key driver of the Company's growth. According to IQDATA, in the first half of 2026, PROMOMED's share in the retail market of GLP-1 receptor agonists reached 59% in monetary terms. Tirzetta® is one of the key growth drivers of the entire commercial pharmaceutical market in Russia. According to the DSM Group, the first domestic tirzepatide became the No. 1 brand in terms of pharmacy sales in January and has held its position throughout the year. In addition to endocrinology, PROMOMED is actively developing areas of oncology and therapy against HIV infection. The Company has recently completed the development cycle of innovative long-acting antiretroviral drugs that were previously unavailable in our country.

The data from analytical agencies clearly confirm the effectiveness of the PROMMED strategy, based on the development and commercialization of the latest solutions in the most sought-after therapeutic areas. The leadership in the DSM Group rating for seven months and the growth rate, which is several times ahead of the market, allow the Company to look to the future with confidence and achieve its goals, including reaching sales of more than 240 billion rubles by 2032.